15:16:42 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-10-30 Kvartalsrapport 2024-Q3
2024-07-25 Kvartalsrapport 2024-Q2
2024-04-29 Ordinarie utdelning MCOV B 1.35 SEK
2024-04-26 Årsstämma 2024
2024-04-26 Kvartalsrapport 2024-Q1
2024-02-09 Bokslutskommuniké 2023
2023-11-03 Kvartalsrapport 2023-Q3
2023-07-26 Kvartalsrapport 2023-Q2
2023-04-28 Ordinarie utdelning MCOV B 1.37 SEK
2023-04-27 Kvartalsrapport 2023-Q1
2023-04-27 Årsstämma 2023
2023-02-17 Bokslutskommuniké 2022
2022-11-03 Kvartalsrapport 2022-Q3
2022-07-22 Kvartalsrapport 2022-Q2
2022-04-28 Ordinarie utdelning MCOV B 1.25 SEK
2022-04-27 Årsstämma 2022
2022-04-27 Kvartalsrapport 2022-Q1
2022-02-11 Bokslutskommuniké 2021
2021-11-03 Kvartalsrapport 2021-Q3
2021-07-23 Kvartalsrapport 2021-Q2
2021-04-30 Ordinarie utdelning MCOV B 0.71 SEK
2021-04-29 Kvartalsrapport 2021-Q1
2021-04-29 Årsstämma 2021
2021-02-12 Bokslutskommuniké 2020
2020-11-06 Kvartalsrapport 2020-Q3
2020-07-24 Kvartalsrapport 2020-Q2
2020-05-04 Ordinarie utdelning MCOV B 0.00 SEK
2020-04-30 Kvartalsrapport 2020-Q1
2020-04-30 Årsstämma 2020
2020-02-14 Bokslutskommuniké 2019
2019-11-06 Kvartalsrapport 2019-Q3
2019-07-26 Kvartalsrapport 2019-Q2
2019-05-06 Ordinarie utdelning MCOV B 0.00 SEK
2019-05-03 Kvartalsrapport 2019-Q1
2019-05-03 Årsstämma 2019
2019-02-15 Bokslutskommuniké 2018
2018-10-26 Kvartalsrapport 2018-Q3
2018-07-27 Kvartalsrapport 2018-Q2
2018-04-27 Ordinarie utdelning MCOV B 0.00 SEK
2018-04-26 Årsstämma 2018
2018-04-26 Kvartalsrapport 2018-Q1
2018-02-09 Bokslutskommuniké 2017
2017-10-27 Kvartalsrapport 2017-Q3
2017-07-28 Kvartalsrapport 2017-Q2

Beskrivning

LandSverige
ListaLarge Cap Stockholm
SektorHälsovård
IndustriVård & Omsorg
Medicover är verksamt inom vård- och omsorg. Affärsverksamheten är inriktad mot servicetjänster inom hälsovård samt diagnostik. Bolaget erbjuder primär- och specialiserad vård, finansieringslösningar samt laboratorietester inom patologi. Huvudmarknaden återfinns runtom den europeiska marknaden med forskningsinstitut som dominerande kundbas. Medicover grundades under 1995 och har sitt huvudkontor i Stockholm.
2019-11-06 07:45:00
Third Quarter
  • Revenue increased by 26.7% to €212.1m (€167.4m). Organic revenue grew by 17.4%.
  • Operating profit (EBIT) increased by 66.7% to €14.3m (€8.6m), representing an operating margin of 6.7% (5.1%).
  • Net profit amounted to €6.3m (€6.7m), which represents a net profit margin of 3.0% (4.0%).
  • EBITDA increased by 41.5% to €32.5m (€23.0m), corresponding to an EBITDA margin of 15.3% (13.7%).
  • EBITDAaL increased by 50.1% to €22.3m (€14.9m), corresponding to an EBITDAaL margin of 10.5% (8.9%).
  • Net cash flow from operating activities was €22.6m (€29.4m).
  • Basic/diluted earnings per share were €0.043 (€0.045).
Nine Months
  • Revenue increased by 25.3% to €614.7m (€490.4m). Organic revenue grew by 15.1%.
  • Operating profit (EBIT) increased by 41.9% to €35.7m (€25.1m), representing an operating margin of 5.8% (5.1%).
  • Net profit amounted to €18.1m (€20.7m), which represents a net profit margin of 2.9% (4.2%) affected by lower other income/costs.
  • EBITDA increased by 31.4% to €87.3m (€66.4m), corresponding to an EBITDA margin of 14.2% (13.5%), impacted by €2.0m (€0.9m) merger and acquisition related costs expensed.
  • EBITDAaL increased by 36.7% to €58.3m (€42.6m), corresponding to an EBITDAaL margin of 9.5% (8.7%).
  • Net cash flow from operating activities amounted to €62.4m (€57.8m).
  • Basic/diluted earnings per share were €0.120 (€0.145).

REVENUE AND EARNINGS

€ millions (€m) Q3 2019 Q3 2018 Growth 9M 2019 9M 2018 Growth FY 2018
Revenue 212.1 167.4 27% 614.7 490.4 25% 671.6
Operating profit 14.3 8.6 67% 35.7 25.1 42% 33.7
Operating profit 6.7% 5.1%   5.8% 5.1%   5.0%
margin, %
Net profit 6.3 6.7 -4% 18.1 20.7 -13% 24.2
Net profit 3.0% 4.0%   2.9% 4.2%   3.6%
margin, %
Basic/diluted 0.043 0.045 -4% 0.120 0.145 -17% 0.167
earnings per
share, €
               
EBITDA 32.5 23.0 41% 87.3 66.4 31% 90.7
EBITDA margin, % 15.3% 13.7%   14.2% 13.5%   13.5%
EBITDAaL 22.3 14.9 50% 58.3 42.6 37% 58.5
EBITDAaL margin, 10.5% 8.9%   9.5% 8.7%   8.7%
%
EBITA 15.7 9.4 67% 39.8 27.0 47% 37.0
EBITA margin, % 7.4% 5.6%   6.5% 5.5%   5.5%

For definition and reconciliation of alternative performance measures, refer to note 11. As from Q3 2019 margins (including margins of comparative figures) and growth rates have been calculated based on EUR whole figures instead of figures rounded in millions.

This is information that Medicover AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication through the agency of the contact person set out below at 7.45 (CET) on 6 November 2019. This interim report and other information about Medicover is available at medicover.com (http://www.medicover.com).

Contact information

For further information, please contact:
Hanna Bjellquist, Head of Investor Relations
Phone: +46 70 303 32 72
E-mail: hanna.bjellquist@medicover.com

Medicover is a leading international healthcare and diagnostic services company and was founded in 1995. Medicover operates a large number of ambulatory clinics, hospitals, specialty-care facilities and laboratories and the largest markets are Poland and Germany. In 2018, Medicover had revenue around €672 million and 20,970 employees. For more information, go to www.medicover.com